Identifying Barriers to Cellular Therapy
Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
What will happen during the trial?
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 400 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Trial Type
- Observational
- Last Update
- 2 weeks ago
- SparkCures ID
- 1797
- NCT Identifier
- NCT06126341
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.